Want to see PMHS full AI Analyst Report?
Polomar Health Services (PMHS) AI Stock Analysis
Polomar Health Services
(Other OTC:PMHS)
The overall score is severely constrained by the company's precarious financial health, marked by deep unprofitability and negative equity, which poses an existential risk. While the dramatic reduction in cash burn and strong revenue growth are notable positives, they are overshadowed by the balance sheet weakness. Technicals show a slight short-term recovery but remain in a broader downtrend, and the negative P/E ratio confirms a lack of earnings-based value.
Polomar Health Services (PMHS) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $4.77M
- Dividend Yield
- ―
- Average Volume (3M)
- 16.21K
- Price to Earnings (P/E)
- -0.5
- Beta (1Y)
- -0.50
- Revenue Growth
- 7688.77%
- EPS Growth
- -359.43%
- Country
- US
- Employees
- 7
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Care Facilities
Polomar Health Services Business Overview & Revenue Model
Company Description
Polomar Health Services, Inc. operates as a retail compounding pharmacy. The company owns SlimRx, a weight loss focused online platform connects patients with licensed physicians to prescribe weight loss medications, such as semaglutide compounded wi...
How the Company Makes Money
null
Polomar Health Services Financial Statement Overview
Summary
Financial performance is critically weak. While revenue growth is exceptional and cash burn has nearly ceased, the company is deeply unprofitable with a -301% net margin and has a negative equity position, raising going-concern risks. The minimal asset base provides no safety net.
Income Statement
35NegativeBalance Sheet
10Very NegativeCash Flow
40Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 3.17M | 648.23K | 58.82K | 0 | 34.53K | 0 |
| Gross Profit | 1.94M | 460.10K | 30.90K | 0 | 34.53K | 0 |
| EBITDA | -85.97K | -776.94K | -1.04M | -410.66K | -181.45K | -132.75K |
| Net Income | -9.46M | -10.70M | -1.34M | -416.50K | -181.12K | -168.40K |
Balance Sheet | ||||||
| Total Assets | 814.73K | 390.04K | 9.95M | 244 | 261.48K | 0 |
| Cash, Cash Equivalents and Short-Term Investments | 178.87K | 132.15K | 6,191 | 244 | 225.62K | 0 |
| Total Debt | 794.79K | 14.86K | 49.18K | 81.66K | 69.70K | 32.69K |
| Total Liabilities | 1.87M | 1.61M | 14.86K | 13.78K | 74.72K | 35.65K |
| Stockholders Equity | -1.06M | -1.22M | 9.94M | -13.54K | 186.77K | -35.65K |
Cash Flow | ||||||
| Free Cash Flow | -6,956 | -396.00K | -1.11M | -371.86K | -40.93K | -32.69K |
| Operating Cash Flow | -6,956 | -396.00K | -1.02M | -371.86K | -40.93K | -32.69K |
| Investing Cash Flow | 0 | 0 | -90.89K | 0 | 0 | 0 |
| Financing Cash Flow | 181.15K | 521.95K | 1.11M | 146.49K | 266.55K | 32.69K |
Polomar Health Services Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PMHS, the sentiment is Positive. The current price of 0.19 is above the 20-day moving average (MA) of 0.14, above the 50-day MA of 0.18, and below the 200-day MA of 0.21, indicating a neutral trend. The MACD of -0.00 indicates Negative momentum. The RSI at 57.87 is Neutral, neither overbought nor oversold. The STOCH value of 90.45 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for PMHS.
Polomar Health Services Risk Analysis
Polomar Health Services disclosed 47 risk factors in its most recent earnings report. Polomar Health Services reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
0 New RisksPolomar Health Services Peers Comparison
Overall Rating
BJDX44Neutral
MNDR43Neutral- PMHS42Neutral
PRFX38Underperform
UPC37Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| BJDX | 44Neutral | $2.49M | -0.05 | -125.01% | ― | ― | 93.91% |
| MNDR | 43Neutral | $1.17M | -0.02 | -35.24% | ― | 4.47% | 92.03% |
| PMHS | 42Neutral | $5.32M | -0.48 | -892.31% | ― | 7688.77% | -359.43% |
| PRFX | 38Underperform | $2.22M | -0.07 | -72.87% | ― | ― | ― |
| UPC | 37Underperform | $7.49M | -0.43 | -3.48% | ― | -8.04% | -100.01% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| PMHS | Polomar Health Services, Inc. | 0.19 | -0.01 | -6.50% | |
| PRFX | Painreform Ltd. | 0.73 | -5.07 | -87.41% | |
| UPC | Universe Pharmaceuticals Incorporation | 1.49 | -3.11 | -67.61% | |
| BJDX | Bluejay Diagnostics, Inc. | 0.56 | -6.56 | -92.19% | |
| NIVF | Newgenivf Group Limited | 0.98 | -10522.54 | -99.99% | |
| MNDR | Mobile-health Network Solutions Class A | 0.98 | -13.18 | -93.10% |
Polomar Health Services Corporate Events
Polomar Health Services Streamlines Board After Director Resignations
NeutralOn October 14, 2026, Polomar Health Services, Inc. saw the resignation of two board members, Alexandra Peterson from the Audit Committee and Gabrielle Toledano from the Compensation Committee, with the Board notified on October 15, 2026. The company...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 30, 2026